In models more closely reflecting lung cancer, afatinib also inhibited survival of NSCLC cell lines expressing L858R/T790M (NCI-H1975) or EGFR E746_A750del (HCC827); while the latter was also sensitive to erlotinib, the former was erlotinib-resistant (Li et al. 2008). Here, EGFR is linked to lung cancer.